Literature DB >> 20126353

Rubinstein-taybi syndrome: a female patient with a de novo reciprocal translocation t(2; 16)(q36.3; p13.3) and dysgranulopoiesis.

Leuridan Cavalcante Torres, Maria de Lourdes Lopes Chauffaille, Thomaz Pileggi Delboni, Thelma Suely Okay, Magda Carneiro-Sampaio, Sofia Sugayama.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 20126353      PMCID: PMC2815272          DOI: 10.1590/S1807-59322010000100016

Source DB:  PubMed          Journal:  Clinics (Sao Paulo)        ISSN: 1807-5932            Impact factor:   2.365


× No keyword cloud information.

INTRODUCTION

Rubinstein-Taybi syndrome (RTS) is a rare developmental disorder characterized by craniofacial dysmorphisms, broad thumbs and toes as well as mental and statural deficiencies.1 RTS has a prevalence of 1 in 330,000 births2 and usually occurs sporadically, although it can be inherited as an autosomal dominant disorder.2,4 The diagnosis is based on characteristic features.3 The main clinical symptoms are failure to thrive, cardiac defects and recurrent respiratory infections.4 Other variable findings are colobomas, cataracts, renal anormalities3,4 and oro-dental anomalies.5 RTS patients also have an increased risk of developing neoplasias.6,7 Several tumors have been reported in RTS patients, including meningiomas, rhabdomyosarcomas, neuroblastomas, oligodendromas, seminomas, choristomas and leukemias.6,7 CREBBP and EP300 are the only genes associated with RTS.8,11 Microdeletions at band 16p13.3 occur in 10%–25% of RTS patients.9 Sequence analyses have detected CREBBP mutations in another 56% of affected individuals. Schorry et al. (2008)8 evaluated genotype-phenotype correlations in 93 RTS patients and performed complete sequencing of all 31 coding regions of the CREBBP gene. The authors concluded that there were no statistically significant differences in the classic dysmorphic findings of RTS patients (e.g., typical facial aspects and broad thumbs and toes) with and without CREBBP mutations. Mutations in EP300 have been identified in 3% of RTS patients.7,9 RTS typically occurs as a de novo mutation in a family.2 Most individuals represent simplex cases (i.e., the only affected member in a family); in most instances, the parents of an individual with RTS are not affected.2,4 In this case, the empiric recurrence risk for siblings is approximately 0.1%. Although individuals with RTS rarely reproduce, the theoretical risk for the offspring is 50%.2 Prenatal testing for at-risk pregnancies is possible if the disease-causing CREBBP mutation or deletion in the family is known.7

CASE DESCRIPTION

The propositus, a 23-year-old Brazilian female patient, is the third child of healthy, non-consanguineous parents. The infant was born pre-term by Cesarean section. The birth weight was 1,900 g, the length was 47 cm, the occipitofrontal circumference (OFC) was 36 cm, and the body mass index was 31.35 (mild obesity). Developmental milestones were delayed: she sat without support at the age of 1, walked at 2.5 years and acquired control of the bowels at age 4. She spoke only a few meaningful words at the age of eighteen. The clinical history of the infancy and childhood was noteworthy, with feeding problems and recurrent respiratory infections (sinusitis, otitis medias, tonsillitis and pneumonias) from two months of age until the age of five. Splenomegaly was observed at 21 years of age, and a detailed immunological analysis of this patient was performed by Torres (2008)13. Persistent mild to moderate leukocytosis (13,000 to 26,000/mm3) was observed despite the absence of clinical signs of infection. Forty to fifty percent of blood neutrophils presented with scarce or absent granules. A myelogram also showed dysgranulopoietic granulocytes. A physical examination at 23 years of age showed a weight of 61 kg (75
Figure 1

A patient with the facial dysmorphisms typical of RTS

Figure 2

Broad and radially deviated thumbs

Chromosome preparations were obtained from peripheral blood lymphocytes from the propositus and her parents. Karyotyping with GTG banding was performed at the 450–550 band level using standard methods9 by the Fleury Laboratory. The patient’s karyotype showed a balanced reciprocal translocation between chromosomes 2 and 16 without visible deletion; the full karyotype is 46, XX, t(2;16) (q36.3; p13.3) (Figure 3). The parent’s karyotypes were normal, so this translocation was de novo. The recurrence risk for the parents is very low (approximately 0.1%).
Figure 3

GTG banding karyotype

DISCUSSION

Chromosomal rearrangements involving band 16p13.3 form the minority (0.6%) of CREBBP mutations.18 There have been seven reported cases of chromosomal rearrangements in RTS patients, and four of these were translocations.14–18 The 4-year-old RTS boy described by Petrij et al. (1995)17 presented with the same translocation (2; 16) with the same breakpoints as our patient. The common clinical findings of this boy and our patient were feeding problems, short stature and recurrent respiratory infections. To the best of our knowledge, our RTS patient is the third reported case with a de novo reciprocal t (2;16) (q36.3; p13.3). We found no other studies describing RTS patients with dysgranulopoietic neutrophils. As RTS patients have an increased risk of hematological malignancies,6 appropriate laboratory testing and hematological follow-up are warranted.
Table 1

Reciprocal translocations in RTS patients

KaryotypeReferences
46, XX, t(2; 16) (p13.3; p13.3)Imaizumi, Kuroki (1991)15
46, XY, t(7; 16) (q34; p13.3)Tommerup et al. (1992) 16
46, XY, t(2; 16) (q36.3; p13.3)Petrij et al. (1995)17; Giles et al. (1997) 19; Petrij et al. (2000) 20
46, XY, t(1; 16) (p34.1; p13.2)Wallerstein et al. (1997)21
  20 in total

1.  Submicroscopic deletions at 16p13.3 in Rubinstein-Taybi syndrome: frequency and clinical manifestations in a North American population.

Authors:  R Wallerstein; C E Anderson; B Hay; P Gupta; L Gibas; K Ansari; F S Cowchock; V Weinblatt; C Reid; A Levitas; L Jackson
Journal:  J Med Genet       Date:  1997-03       Impact factor: 6.318

2.  Oro-dental features as useful diagnostic tool in Rubinstein-Taybi syndrome.

Authors:  A Bloch-Zupan; J Stachtou; D Emmanouil; B Arveiler; D Griffiths; D Lacombe
Journal:  Am J Med Genet A       Date:  2007-03-15       Impact factor: 2.802

Review 3.  Rubinstein-Taybi syndrome: clinical and molecular overview.

Authors:  Jeroen H Roelfsema; Dorien J M Peters
Journal:  Expert Rev Mol Med       Date:  2007-08-20       Impact factor: 5.600

4.  Construction of a 1.2-Mb contig surrounding, and molecular analysis of, the human CREB-binding protein (CBP/CREBBP) gene on chromosome 16p13.3.

Authors:  R H Giles; F Petrij; H G Dauwerse; A I den Hollander; T Lushnikova; G J van Ommen; R H Goodman; L L Deaven; N A Doggett; D J Peters; M H Breuning
Journal:  Genomics       Date:  1997-05-15       Impact factor: 5.736

Review 5.  Etiology and recurrence risk in Rubinstein-Taybi syndrome.

Authors:  R C Hennekam; C A Stevens; J J Van de Kamp
Journal:  Am J Med Genet Suppl       Date:  1990

6.  Variation in microdeletions of the cyclic AMP-responsive element-binding protein gene at chromosome band 16p13.3 in the Rubinstein-Taybi syndrome.

Authors:  R I Blough; F Petrij; J G Dauwerse; A Milatovich-Cherry; L Weiss; H M Saal; J H Rubinstein
Journal:  Am J Med Genet       Date:  2000-01-03

7.  Spectrum of CREBBP gene dosage anomalies in Rubinstein-Taybi syndrome patients.

Authors:  Marianne Stef; Delphine Simon; Béatrice Mardirossian; Marie-Ange Delrue; Ingrid Burgelin; Christophe Hubert; Michèle Marche; Françoise Bonnet; Philippe Gorry; Michel Longy; Didier Lacombe; Isabelle Coupry; Benoît Arveiler
Journal:  Eur J Hum Genet       Date:  2007-05-02       Impact factor: 4.246

8.  Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP.

Authors:  F Petrij; R H Giles; H G Dauwerse; J J Saris; R C Hennekam; M Masuno; N Tommerup; G J van Ommen; R H Goodman; D J Peters
Journal:  Nature       Date:  1995-07-27       Impact factor: 49.962

Review 9.  Tumors in Rubinstein-Taybi syndrome.

Authors:  R W Miller; J H Rubinstein
Journal:  Am J Med Genet       Date:  1995-03-13

10.  Rubinstein-Taybi Syndrome: spectrum of CREBBP mutations in Italian patients.

Authors:  Angela Bentivegna; Donatella Milani; Cristina Gervasini; Paola Castronovo; Federica Mottadelli; Stefano Manzini; Patrizia Colapietro; Lucio Giordano; Francesca Atzeri; Maria T Divizia; Maria L Giovannucci Uzielli; Giovanni Neri; Maria F Bedeschi; Francesca Faravelli; Angelo Selicorni; Lidia Larizza
Journal:  BMC Med Genet       Date:  2006-10-19       Impact factor: 2.103

View more
  4 in total

1.  Rubinstein-Taybi syndrome: Clinical profile of 11 patients and review of literature.

Authors:  Suresh Kumar; Renu Suthar; Inusha Panigrahi; Ram K Marwaha
Journal:  Indian J Hum Genet       Date:  2012-05

2.  Further peer review failures.

Authors:  Horacio Rivera
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

3.  Thyroid hypoplasia as a cause of congenital hypothyroidism in monozygotic twins concordant for Rubinstein-Taybi syndrome.

Authors:  Mustafa Ali Akın; Tamer Güneş; Leyla Akın; Dilek Çoban; Sena Kara Oncu; Aslıhan Kiraz; Selim Kurtoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2011-02-23

4.  Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.

Authors:  João Agostinho Machado-Neto; Fabiola Traina; Mariana Lazarini; Paula de Melo Campos; Katia Borgia Barbosa Pagnano; Irene Lorand-Metze; Fernando Ferreira Costa; Sara T Olalla Saad
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.